Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?
暂无分享，去创建一个
[1] M. Curran,et al. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. , 2016, The Journal of investigative dermatology.
[2] M. Sweetser,et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. , 2005, Clinical therapeutics.
[3] M. Lebwohl,et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. , 2003, Archives of dermatology.